Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma

Susana Puig(Universitat de Barcelona), Míriam Potrony(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Francisco Cuéllar(Consejo Nacional de Humanidades, Ciencias y Tecnologías), Joan Anton Puig‐Butillé(Instituto de Salud Carlos III), Cristina Carrera(Centre for Biomedical Network Research on Rare Diseases), Paula Aguilera(Instituto de Salud Carlos III), Eduardo Nagore(Valencia Catholic University Saint Vincent Martyr), Zaida García‐Casado(Fundación Instituto Valenciano de Oncología), Celia Requena(Fundación Instituto Valenciano de Oncología), Rajiv Kumar(Heidelberg University), Gilles Landman(AC Camargo Hospital), Bianca Costa Soares de Sá(AC Camargo Hospital), Gisele Gargantini Rezze(AC Camargo Hospital), Luciana Facure(AC Camargo Hospital), Alexandre Avila(AC Camargo Hospital), Maria Isabel Achatz(AC Camargo Hospital), Dirce Maria Carraro(AC Camargo Hospital), João Pedreira Duprat Neto(AC Camargo Hospital), Thaís Corsetti Grazziotin(Universidade Federal de Ciências da Saúde de Porto Alegre), Renan Rangel Bonamigo(Universidade Federal de Ciências da Saúde de Porto Alegre), Maria Carolina Widholzer Rey(Universidade Federal de Ciências da Saúde de Porto Alegre), Claudia Balestrini(Complejo Asistencial Sótero del Río), Enrique Morales(Hospital San Juan de Dios), Montserrat Molgó(Pontificia Universidad Católica de Chile), Renato Marchiori Bakos(Universidade Federal do Rio Grande do Sul), Patrícia Ashton‐Prolla(Universidade Federal do Rio Grande do Sul), Roberto Giugliani(Universidade Federal do Rio Grande do Sul), Alejandra Larre Borges(Hospital de Clínicas), V. Barquet(Hospital de Clínicas), J. Gómez Pérez(Universidad de la República), Miguel Ángel Martínez(Hospital de Clínicas), Horacio Cabo(Institute for Medical Research), Emilia Cohen Sabban(Institute for Medical Research), Clara Villar Latorre, Blanca Carlos‐Ortega(Centro Médico Nacional La Raza), Julio C. Salas‐Alanís(University of Monterrey), Roger González(Universidad Autónoma de Nuevo León), Zulema Olazaran(Hospital Universitario Dr José Eleuterio Gonzalez), Josep Malvehy(Instituto de Investigación de Enfermedades Raras), Célia Bádenas(Instituto de Investigación de Enfermedades Raras)
Genetics in Medicine
December 17, 2015
Cited by 37Open Access
Full Text

Abstract

PURPOSE: CDKN2A is the main high-risk melanoma-susceptibility gene, but it has been poorly assessed in Latin America. We sought to analyze CDKN2A and MC1R in patients from Latin America with familial and sporadic multiple primary melanoma (SMP) and compare the data with those for patients from Spain to establish bases for melanoma genetic counseling in Latin America. METHODS: CDKN2A and MC1R were sequenced in 186 Latin American patients from Argentina, Brazil, Chile, Mexico, and Uruguay, and in 904 Spanish patients. Clinical and phenotypic data were obtained. RESULTS: Overall, 24 and 14% of melanoma-prone families in Latin America and Spain, respectively, had mutations in CDKN2A. Latin American families had CDKN2A mutations more frequently (P = 0.014) than Spanish ones. Of patients with SMP, 10% of those from Latin America and 8.5% of those from Spain had mutations in CDKN2A (P = 0.623). The most recurrent CDKN2A mutations were c.-34G>T and p.G101W. Latin American patients had fairer hair (P = 0.016) and skin (P < 0.001) and a higher prevalence of MC1R variants (P = 0.003) compared with Spanish patients. CONCLUSION: The inclusion criteria for genetic counseling of melanoma in Latin America may be the same criteria used in Spain, as suggested in areas with low to medium incidence, SMP with at least two melanomas, or families with at least two cases among first- or second-degree relatives.Genet Med 18 7, 727-736.


Related Papers

No related papers found

Powered by citation graph analysis